Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for 100 million doses of COVID-19 vaccines covering 50 million people and underwrite the drug makers’ testing and manufacturing.
Each of the 50 million Americans will receive two doses.
The deal will cost around $42 per person inoculated.
Sanofi and GlaxoSmithKline would conduct clinical trials for the vaccine in September.
The US government has the option to purchase an additional 500 million doses at an unspecified price.
Sanofi executive Clement Lewin said the companies have yet to agree with the government on the price for the additional doses.
According to Alex Azar, secretary of the US Department of Health and Human Services, the product being developed by Sanofi and GSK has the potential to bring hundreds of millions of safe and effective doses.
The award is so far the biggest from the White House initiative to accelerate access to vaccines and treatments to fight COVID-19 dubbed ‘Operation Warp Speed.’
Last week, the US agreed to pay Pfizer Inc and BioNTech SE $2 billion deal for 50 million courses of the potential vaccine.
The price per patient is $40.
The coronavirus has infected 4.5 million Americans and killed over 152,000 Americans.
The US Centers for Disease Control forecasts between 168,000 and 182,000 total fatalities by August 22.
The deaths will supposedly rise fastest in Alabama, Tennessee, Washington state, Kentucky, New Jersey, and Puerto Rico.
